Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Crizanlizumab by Novartis for Myelofibrosis: Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...